DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1658)

Axial Spondyloarthritis | Unmet Need | Detailed, Expanded Analysis (US & EU)

Axial Spondyloarthritis | Unmet Need | Detailed, Expanded Analysis (US & EU)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.


What are the treatment drivers and goals for [[indication]]?
What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals for [[indication]]?
What are the prevailing areas of unmet need and opportunity in [[indication]]?
What trade-offs across different clinical attributes and price are acceptable to and European [[physician type, plural]] for a hypothetical new [[indication]] drug?

Provides quantitative insight into and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of [[XX]] and [[XX]] European [[physician type, plural]] fielded in [[Month. Year]]
Key companies:  [[key company 1]], [[key company 2]], [[key company 3]]
Key drugs: [[key drug 1]], [[key drug 2]], [[key drug 3]]

  • Pub Date: February 2018
  • Author(s): Hailing Yang, PhD

Request report

Related reports:
You may also be interested in: